Screener
BridgeBio Pharma BBIO Stock Issuance Proceeds
Stock Issuance Proceeds at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromStockOptionsExercised.
The source filing: BridgeBio Pharma’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:31 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001743881-26-000019
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Repayment of term loans | — | (459,000) |
| Repayments of deferred royalty obligations (3) | (11,293) | (144) |
| Proceeds from common stock issuances under ESPP | 5,466 | 3,237 |
| Proceeds from stock option exercises, net of repurchases | 22,589 | 2,521 |
| Transactions with noncontrolling interests | — | 800 |
| Repurchase of RSU shares to satisfy tax withholding | (4,074) | (1,776) |
| Net cash provided by financing activities | 549,892 | 60,328 |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | 309,878 | (140,502) |
Item 1. Financial Statements (Unaudited)
FAQ
- What is BridgeBio Pharma's stock issuance proceeds?
- BridgeBio Pharma (BBIO) reported stock issuance proceeds of $22.59M in Q1 2026.
- What does stock issuance proceeds mean?
- Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.
Ask your AI about BridgeBio Pharma's stock issuance proceeds.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude